U.S. Markets closed

FDA declines to approve Adamis Pharma's Zimhi to treat opioid overdose

Nov 25 (Reuters) - Adamis Pharmaceuticals Corp said on Monday its opioid overdose treatment was rejected by the U.S. Food and Drug Administration.

In a letter to the company, the FDA raised questions about the treatment's chemistry and manufacturing but not about its safety or effectiveness, Adamis said.

The drug Zimhi is a naloxone pre-filled single dose syringe used for the emergency treatment of known or suspected opioid overdose.

(Reporting by Shivani Singh and Manojna Maddipatla in Bengaluru; Editing by Shinjini Ganguli)